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1. Introduction 
In a large number of eukaryotes iron is stored in a 
soluble non-toxic form in ferritin. The iron is depos- 
ited in the interior of an approximately spherical pro- 
tein shell, predominantly as ferric oxyhydroxide 
(reviewed [ 1,2] ). A number of mechanisms have 
been proposed for ferritin iron release involving low 
molecular weight chelators [3,4], enzyme systems 
such as xanthine oxidase [S] or a ferriductase [6], 
and more recently by reduction of the ferric iron by 
reduced flavins [7-l 01, followed. by chelation by a 
suitable complexing agent. 
The direct mobilisation of ferritin iron by chelators 
does not seem to be a likely mechanism in vivo. The 
development of a chelator that could directly 
mobilise storage iron in a form that could be easily 
eliminated from the body, would be of considerable 
interest in the treatment of disorders of iron metab- 
olism characterized by secondary iron overload. 
Such a clinical situation is encountered in Cooley’s 
anaemia, where the consequence of prolonged blood 
transfusion is the accumulation of finally toxic levels 
of iron in liver, heart and other tissues. 
We have examined the release of ferritin iron in 
vitro by the iron chelators: 2,2’-bipyridyl, desferriox- 
amine B, rhodotorulic acid, 2,3-dihydroxybenzoate, 
and the bipyridyl analogue, pyridine-2-aldehyde-2- 
pyridyl hydrazone (Paphy). The effects of a number 
of molecules that might assist in mediating iron release 
between the ferritin iron core and the chelators was 
also studied. 
2. Materials and methods 
Horse spleen ferritin was obtained from Boehringer 
(Mannheim), Mops (morpholine propane sulphonic 
Elsevicr/North-Holland Biomedical Press 
acid) from Serva (Heidelberg), 2,3-dihydroxybenzoate 
and Paphy (pyridine-2-aldehyde-2-pyridyl hydrazone) 
from Aldrich (Beerse). Desferrioxamine B was a gift 
from Ciba-Geigy (Basle) and rhodotorulic acid was a 
gift from Dr A. Cerami, Rockefeller University, 
New York). FMN was from Serva (Heidelberg) and 
NADH from Boehringer (Mannheim). Ascorbate and 
EDTA were from Merck (Darmstadt). 
Ferritin protein and iron concentration were deter- 
mined by amino acid analysis and by the method of 
[ Ill, respectively. The h,, for the various iron 
chelators was determined in 200 mM Mops buffer 
(pH 7.4) as in [ 111. Iron release from ferritin was 
followed at the appropriate X,,, by incubation of 
ferritin (final cont. 10m6 M in protein) in 200 mM 
Mops buffer (pH 7.4) together with the chelator at 
1 mM final cont. in a waterbath at 37°C. The samples, 
in 1 ml final vol. in disposable cuvettes (Kartell, 
Milan) were removed at appropriate time intervals 
and the amount of iron released determined spectro- 
photometrically. 
The mean f SE for 5 samples was determined. In 
the experiments with FMN, ascorbate and EDTA, 
these latter substances were introduced into the reac- 
tion medium at 1 mM final cont. The appropriate 
controls which were used for FMN with bipyridyl and 
Paphy are described in [ Ill. 
3. Results and discussion 
Iron release from ferritin by the five chelators 
studied are presented in fig.1. We can readily establish 
that rhodotorulic acid and desferrioxamine B (which 
are both trihydroxamic acids) release the greatest 
amounts of iron, and over 24 h incubation at 37’C, 
liberate 250 g atoms and 225 g atoms iron/ferritin 
molecule, respectively. Of the other chelators only 
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Fig.1. Iron release from ferritin by chelators. Iron release 
from horse spleen ferritin was measured as in section 2 and is 
expressed as g atoms Fe/molecule released at the appropriate 
time interval; the standard errors are indicated by error bars. 
The chelators employed (at 1 mM final con.) are: (1) Paphy; 
(2) bipyridyl; (3) desferrioxamine B; (4) rhodotorulic acid; 
(5) 2,3dihydroxybenzoate. 
Paphy gives a reasonable release of 85 g atoms/ferri- 
tin molecule in 24 h whereas the release of iron by 
2,3-dihydroxybenzoate does not evolve significantly 
from the plateau value observed in fig.1 even after 
24 h incubation. 
When we turn to the effects of the mediators, we 
can consider first the effects of the reducing agent 
ascorbate and the complexant EDTA; the results are 
presented in table 1, A slight positive effect was 
observed with desferrioxamine B in the presence of 
ascorbate, and a more important increase correspond- 
ing to 30% after 6 h with EDTA. With rhodotorulic 
acid, ascorbate also had a positive effect on iron 
mobilisation, but EDTA inhibited iron release 
markedly; after 6 h the amount of iron released in the 
presence of EDTA was reduced to 40% of the control 
value. The stimulatory effect of ascorbate could be 
explained by reduction of ferritin iron and its release 
from ferritin as a Fe II-ascorbate complex which 
thereafter is transfered to the hydroxamic acid. 
EDTA might act by chelating the ferritin iron directly: 
the transfer of iron from the Fe II-EDTA complex 
to the hydroxamic acid would be determined by the 
relative stability constants of the Fe-EDTA and Fe- 
hydroxamate and by the kinetics of iron exchange 
between the two chelators. 
For bipyridyl and Paphy the effects of ascorbate 
and EDTA were very similar. For both chelators, 
ascorbate considerably increased ferritin iron release; 
after 6 h a 7-fold increase was observed for bipyridyl 
and a 2-fold increase for Paphy. This presumably 
reflects the preferential binding by these chelators of 
Fe II. EDTA virtually eliminated iron mobilisation by 
Paphy and bipyridyl, consistent with the higher 
affinity of EDTA for Fe III compared to the pyri- 
dinium derivatives. 
Both ascorbate and EDTA inhibited iron release 
from ferritin by 2,3-dihydroxybenzoate, although the 
effect of EDTA was much greater than that of ascor- 
bate. 
For FMN at 1 mM final cont. the results are 
presented in table 2. It should be emphasized that all 
of the results were obtained with continuous illumin- 
ation of the samples by standard strip lighting during 
the period of incubation. The results can be divided 
into 3 groups: 
Table 1 
Effect of ascorbate and EDTA on iron release from ferritin by chelating agents 
Chelator Iron release (g atom/molecule of ferritin) after 
incubation 
No addition + Ascorbate + EDTA 
2h 6h 2h 6h 2h 6h 
Desferrioxamine B 62.1 116.8 71.9 136.1 83.1 154.5 
Rhodotorulic acid 13.9 147.7 87.5 179.3 59.3 63.2 
2,3-Dihydroxybenzoate 24.4 35.5 18.9 28.0 12.7 15.5 
Bipyridyl 5.7 9.1 35.2 71.4 2.4 2.8 
Paphy 22.4 49.3 52.0 131.5 1.5 6.1 
In all experiments, the final concentration of ascorbate, of EDTA and of the 
chelator was 1 mM in 200 mM Mops buffer (pH 7.4). All results were obtained at 
37°C with continuous illumination 
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Table 2 
Effect of FMN on iron release from ferritin by chelating 
agents 
Chelator Iron release (g atom/molecule 
ferritin) after incubation 
2h 6h 24 h 
Desferrioxamine B 11.7 12.3 12.6 
Rhodotorulic acid 21.9 21.5 22.3 
2,3-Dihydroxybenzoate 26.1 26.0 26.8 
Bipyridyl 15.8 41.3 116.5 
Paphy 48.5 89.3 122.0 
In all experiments the final concentration, both of FMN and 
of the chelator, was 1 mM in 200 mM Mops buffer (pH 7.4). 
All results were obtained at 37°C with continuous illumination 
(1) 
(2) 
Desferrioxamine B and rhodotorulic acid which, 
although the most effective chelators of ferritin 
iron in the absence of mediators, are almost com- 
pletely inhibited by 1 mM FMN. The small 
amount of ferritin iron released in the course of 
the 1 h incubation does not evolve over the next 
24 h. Therefore, either the FMN (probably in a 
reduced form) blocks access of the chelators to 
the sites of iron mobilisation, or else that the 
presence of small amounts of reduced FMN 
generates Fe II on the sites of mobilisation, and 
that the chelators (which certainly prefer Fe III 
to Fe II) do not have a sufficient affinity for the 
Fe II to be able to displace it from the sites. 
Bipyridyl and Paphy: Despite the problems asso- 
ciated with compensating for the absorption of 
photoreduced FMN in the,assay system (see 
[ 1 l] ) we observed a substantial enhancement of 
iron mobilisation by these 2 chelators in the 
presence of FMN, and of light; no difference, 
compared to control samples without flavin, was 
observed in the absence of light (R. R. C., F. R. 
unpublished). Since both bipyridyl and Paphy 
are good Fe II chelators (and since in the case of 
bipyridyl, the Fe III complex is not detected at 
the wavelength used), the increased iron release 
observed in the presence of FMN must reflect 
photoreduction of some of the FMN accompanied 
by reduction of ferritin iron. This is in complete 
accord with the observations [7-lo] that ferri- 
tin iron is most effectively mobilised by reduc- 
tion with reduced flavins prior to its complex- 
ation. 
(3) For 2,3-dihydroxybenzoate a slight inhibition 
was observed. It should however be emphasized 
that, whereas this chelator rapidly releases ome 
40 g atoms iron/ferritin molecule (fig.1) no 
further iron release is observed. 
In conclusion we have found that of the iron 
chelators currently employed for the treatment of 
iron overload (desferrioxamine B, rhodotorulic acid 
and 2,3-dihydroxybenzoate) the two hydroxamic 
acid derivatives are effective in ferritin iron mobili- 
sation, but are almost completely inhibited in the 
presence of 1 mM FMN. Since there are good reasons 
to believe that the release of iron in vivo involves 
preliminary reduction of the ferritin iron by a reduced 
flavin, and that ferritin prepared by standard proce- 
dures [ 1 ,121 contains a flavin (J. C. M., R. R. C., 
unpublished), the mobilisation of ferritin iron by 
desferrixoamine B and by rhodotorulic acid in vivo 
may be inhibited, and that iron release by these 
chelators in vivo most probably reflects the capture of 
iron from a transit pool situated between intracellular 
storage iron (ferritin) and extracellular transport 
iron (transferrin) as suggested in [13,14]. Dihydroxy- 
benzoate does not seem to be a likely candidate for 
direct mobilisation of ferritin iron in vitro. In con- 
trast, chelators of Fe II such as bipyridyl and Paphy 
are well suited to take advantage of the reduction of 
ferritin iron by reduced flavins and may represent a 
potential approach to the direct mobilisation of 
ferritin iron in vivo. In cultured rat fibroblasts, 
bipyridyl, desferrioxamine B and 2,3-dihydroxyben- 
zoate substantially diminish the intracellular accumu- 
lation of transferrin iron [ 151. The study, in parallel, 
of in vitro and in vivo ferritin iron mobilisation may 
offer the most rational and appropriate method for 
the development of new iron chelators. 
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